Neuronetics Dividend

Dividend criteria checks 0/6

Neuronetics hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.7%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$1.01
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Mar 17

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Aug 29

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Aug 02

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

Jul 19

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Jun 08

Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Jan 19

Is Neuronetics (NASDAQ:STIM) Using Debt In A Risky Way?

Oct 14

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Jul 05

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von STIM in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von STIM gestiegen sind.

Dividend Yield vs Market

Neuronetics Dividend Yield vs Market

How does STIM dividend yield compare to the market?
Segment	Dividend Yield
Company (STIM)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Medical Equipment)	1.7%
Analyst forecast in 3 Years (STIM)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von STIM im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von STIM im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von STIM, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da STIM keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Neuronetics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022)

Executive VP notifies of intention to sell stock

President recently sold US$71k worth of stock

President notifies of intention to sell stock

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Executive VP recently sold US$53k worth of stock

Executive VP notifies of intention to sell stock

Executive VP recently sold US$52k worth of stock

Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System

Executive VP notifies of intention to sell stock

Neuronetics: Modest Improvements Are Not Enough

President recently sold US$60k worth of stock

Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023

Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory

Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan

New minor risk - Share price stability

Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal

Consensus EPS estimates upgraded to US$1.15 loss

Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans

Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

Executive VP recently sold US$58k worth of stock

Executive VP notifies of intention to sell stock

Price target decreased by 10% to US$8.67

President recently sold US$214k worth of stock

President notifies of intention to sell stock

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

High number of new directors

Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health

Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022

Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023

Consensus estimates of losses per share improve by 10%

Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

President exercised options to buy US$341k worth of stock.

Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform

Neuronetics: Growth To Capture, But Fairly Priced

Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Senior VP notifies of intention to sell stock

President recently sold US$236k worth of stock

Neurostics Inc. Receives U.S. Food and Drug Administration Clearance for Treatment of Anxious Depression

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

President notifies of intention to sell stock

Cannell Capital LLC Communicates with Neuronetics Inc

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Neuronetics, Inc. Provides Earning Guidance for the Second Quarter and Full Year of 2022

Neurostar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

High number of new directors

Neuronetics, Inc., Annual General Meeting, May 26, 2022

Consensus EPS estimates fall by 37%

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$9.67

Neuronetics, Inc. Announces the Commercial Launch of the MT Cap in the U.S